Aileron Therapeutics' Phase 1b trial of inhaled LTI-03 showed positive trends in seven out of eight IPF biomarkers. LTI-03 reduced SPD by 5% at 14 days, outperforming current IPF standard care's 4% ...
Savannah is a technology journalist in Rochester, Minnesota. Her specialties include gaming, E ink, computer hardware, and smart homes. If her status is away, she can most likely be found paddling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results